Collapsing glomerulopathy: Update

Morales, Enrique; Alonso, Marina; Gutiérrez, Eduardo

doi:10.1016/j.medcle.2019.02.018

Cited by 9 publications

(11 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, 47 out of 50 cases (94%) exhibited mesangial deposits by immunofluorescence and electron microscopy, while most patients with complete nephrotic syndrome had >70% diffuse foot process effacement [56]. In African American patients with LN and FSGS features on kidney histology, one must consider testing for APOL1 G1 and G2 risk alleles due to its association with collapsing glomerulopathy [57]. Regarding treatment of LP, most cases respond to a short cycle of high-dose steroids; however, high relapse rates have been reported in a subset of patients.…”

Section: Special Situations (Lupus Podocytopathy Membranous Nephropamentioning

confidence: 99%

Update on Lupus Nephritis: Looking for a New Vision

Morales

Galindo

Trujillo

et al. 2020

Nephron

Self Cite

View full text Add to dashboard Cite

Lupus nephritis (LN) is one of the most common manifestations of systemic lupus erythematosus (SLE), affecting approximately 40% of patients with lupus. It represents a major risk factor for morbidity and mortality, and 10% of patients with LN will develop end-stage kidney disease (ESKD). Therefore, there are a number of areas for improvement in the field of LN such as the search for new clinical biomarkers with a more accurate correlation with lupus activity and the redefinition of the histological classification into different subgroups in order to guide a personalized treatment. Although the role of protocol repeat kidney biopsies in LN is controversial, recent publications suggest that repeat histological assessment can be useful in guiding therapeutic decisions that may yield toward precision medicine. In the last decade, LN therapy has remained largely unchanged, with a probability of achieving complete or partial remission not exceeding 60–70%. Thus, optimization of old treatment strategies and search for new agents are urgently needed in order to improve outcomes such as mortality or development of ESKD. Future trials should focus in addressing unanswered issues such as the appropriate dose and duration of immunosuppressive treatment, timing of steroid withdrawal, and drug toxicity. In addition, data are still lacking regarding pregnancy and kidney transplantation in LN and knowledge about these important areas is essential for the management of a subset of patients with SLE. In summary, several major gaps are still present in the therapeutic approach and follow-up of patients with LN. The development of new clinical trial designs will be crucial in the search to improve long-term outcomes.

show abstract

Section: Special Situations (Lupus Podocytopathy Membranous Nephropamentioning

confidence: 99%

Update on Lupus Nephritis: Looking for a New Vision

Morales

Galindo

Trujillo

et al. 2020

Nephron

Self Cite

View full text Add to dashboard Cite

show abstract

“…CG can be associated with a wide variety of inflammatory conditions (such as systemic lupus erythematosus), glomerular ischemic insult (thrombotic microangiopathy, sickle cell disease), drugs (anthracycline, pamidronate and interferon) and infections (HIV, hepatitis B and C, parvovirus B19, cytomegalovirus, Epstein-Barr virus). 3 , 4 …”

mentioning

confidence: 99%

Collapsing glomerulopathy following SARS-CoV-2 adenovirus-vector–based vaccine: report of 2 cases

Neves

Caires

Guimarães

et al. 2022

Kidney International

View full text Add to dashboard Cite

“…A glomerulopathy that has been associated with viral infections, autoimmune conditions, and medications [11,12]. It has also been associated with a variant of the apolipoprotein L1 (APOL1) gene seen in blacks [13].…”

Section: Discussionmentioning

confidence: 99%

COVID-19 associated collapsing glomerulopathy presenting as acute kidney injury on chronic kidney disease: a case report and review of the literature

et al. 2021

View full text Add to dashboard Cite

Traditionally collapsing glomerulopathy (CG) is associated with medications, autoimmune disease, viral infection and the APOL1 gene variant seen in blacks/African Americans. Most reported cases of acute kidney injury (AKI) in COVID-19 infected individuals have been in individuals without prior CKD. In this report, we present a 49-year-old African American female with a past medical history of chronic kidney disease (CKD) stage 4, hypertension, type 2 diabetes mellitus, recent COVID-19 infection, and a repeat positive blood test for COVID-19 more than 21 days after the initial result, who presented with an AKI on CKD. Renal biopsy revealed a collapsing glomerulopathy. She was started on hemodialysis and did not receive immunosuppressive therapy due to the advanced scaring seen on the renal biopsy. Concerning the pathophysiology of COVID-19-associated CG, researchers have postulated different mechanisms such as a direct cytopathic effect of the virus on podocytes, immune dysregulation, and fluid imbalance. This is one of a few cases of AKI on CKD due to CG related to COVID-19. The mechanism of CG was, however, unclear. Currently, there is no specific interventions to prevent the development of CG in patients with COVID-19 infection. Further studies should investigate measures to prevent the development of CG.

show abstract

Collapsing glomerulopathy: Update

Cited by 9 publications

References 50 publications

Update on Lupus Nephritis: Looking for a New Vision

Update on Lupus Nephritis: Looking for a New Vision

Collapsing glomerulopathy following SARS-CoV-2 adenovirus-vector–based vaccine: report of 2 cases

COVID-19 associated collapsing glomerulopathy presenting as acute kidney injury on chronic kidney disease: a case report and review of the literature

Contact Info

Product

Resources

About